Form 4: Vanda Pharmaceuticals Director Stephen Mitchell Granted Significant Restricted Stock Unit Award

Vanda Pharmaceuticals Inc. Director Stephen Ray Mitchell was granted 59,225 restricted stock units (RSUs) on June 5, 2025, which are set to vest on June 5, 2026.

Summary

• Stephen Ray Mitchell, a Director of Vanda Pharmaceuticals Inc. (VNDA), acquired 59,225 shares of common stock.
• The transaction, an acquisition of shares, occurred on June 5, 2025, at a price of $0 per share.
• These shares represent a time-based restricted stock unit (RSU) award.
• The RSU award will fully vest on June 5, 2026, contingent upon Mr. Mitchell's continuous service to the company through that date.
• Following this reported transaction, Mr. Mitchell beneficially owns a total of 104,082 shares of Vanda Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally positive as it aligns management's interests with shareholders, but it's a routine compensation event rather than a major strategic announcement that would significantly alter the company's outlook.

Positives

• The grant of 59,225 restricted stock units (RSUs) to a director aligns his interests with long-term shareholder value.
• The time-based vesting schedule encourages continuous service and commitment from the director to the company's success.

Risks

• The vesting of the RSU award is contingent on continuous service, meaning the shares could be forfeited if the director's service terminates before June 5, 2026.
• The ultimate value of the RSU award upon vesting is dependent on Vanda Pharmaceuticals' stock price at that future date, introducing market risk.

Future Outlook

The RSU award is structured to vest on June 5, 2026, contingent on continuous service, indicating a future milestone for the director's equity compensation and continued alignment with company performance.

Industry Context

Equity grants like Restricted Stock Units (RSUs) are a common form of executive and director compensation in the pharmaceutical and biotechnology industries. This practice aims to attract and retain key talent while aligning insider interests with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity-based compensation, particularly through restricted stock units (RSUs), is a standard practice across the biotechnology and pharmaceutical sectors for attracting and retaining key talent and aligning management incentives with shareholder returns.
• The grant of 59,225 RSUs to a director is a significant award, comparable to grants seen at similar-sized biopharmaceutical companies, though the specific value depends on Vanda Pharmaceuticals' stock price at vesting.
• The one-year cliff vesting schedule (vesting 100% on June 5, 2026) is a common, though not universal, vesting schedule for director equity awards, often used to ensure commitment over a specific period.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the award is directly tied to the company's stock performance. It also represents potential future dilution upon vesting, which is a standard consideration for equity compensation plans.
• Management/Directors: The grant provides a significant incentive for the director to remain with the company and contribute to its long-term success.

Next Steps

• Vesting of the 59,225 restricted stock units on June 5, 2026, contingent on continuous service by the reporting person.

Key Dates

Recommendation

Keywords

Vanda Pharmaceuticals, VNDA, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director compensation, beneficial ownership